Top of page
Health

BMS, Disability Solutions launches program to ensure disability diversity in clinical trials

Bristol Myers Squibb (BMS) has entered a partnership with US-based non-profit organisation Disability Solutions for the Disability Diversity in Clinical Trials (DDiCT) initiative to ensure equal access to clinical trials, ensuring all patient groups are ‘reflective of the real-world population’.

This new initiative aligns with Bristol Myers Squibb’s broader inclusion and diversity health equity commitments to address health disparities, clinical trial diversity, supplier diversity, employee giving, and workforce representation between 2020 and 2025.

The DDiCT initiative initially aims to make recommendations on how to effectively improve access, engagement, speed of enrollment, and participation of people with disabilities in clinical trials, to ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies. This project was initiated by the Bristol Myers Squibb People & Business Resource Group DAWN(Disability Advancement Workplace Network) and will be co-led by DAWN and the Global Drug Development Team.

“Through this work, Bristol Myers Squibb can set the standard and stage for access to life-changing and life-saving medicines for people with disabilities,” said Samit Hirawat, M.D., executive vice president and chief medical officer, Global Drug Development, Bristol Myers Squibb. “The long-term goal of our DDiCT program is to develop and pilot trials that are accessible to the widest variety of patients.”

Current common clinical trial practices exclude up to one-fourth of the U.S. population-based on disability status. According to a study published in the Journal of the American Medical Association, in 338 phase III and IV studies, 12.4% of people with intellectual or developmental disabilities and 1.8% of those with physical disabilities failed to be included due to explicit exclusion criteria. The study also identified that additional barriers for disability diversity within clinical trials are caused by inaccessible trial sites, medical equipment, and ableist biases which deter this community from receiving potentially life-saving treatments.

“People with disabilities are omitted from conversations about diversity and inclusion, despite being the largest underrepresented group in the world and the only underrepresented group anyone can join at any given moment. Therefore, it’s essential that we broaden the scope of medical trials and research,” said Tinamarie Duff, DAWN Global People & Business Resource Group Lead, Bristol Myers Squibb. “The launch of the DDiCT, especially during Disability Pride Month, supports Bristol Myers Squibb’s overall commitment to address every dimension of diversity, which means making the most effective medicine to include people with disabilities at all stages of access/trials.”

You might also like

Female doctor consulting patient at the desk in hospital Female doctor consulting patient at the desk in hospital

Sensory nerves help maintain bone health during mechanical loading

Mechanical loading is important for maintaining bone mass, and researchers…

Deaf female patient visiting young male doctor Deaf female patient visiting young male doctor

Deaf patients get poor NHS care, case history suggests

Deaf patients get a raw deal in NHS hospitals, suggests…

Neurons and nervous system Neurons and nervous system

Researchers to develop treatments for children with neurodevelopmental disabilities

Researchers at UC Davis Health and the University of Pennsylvania…

Patients who have suffered a stroke perform recovery activities with the help of nurses in the recovery program at Hospital Patients who have suffered a stroke perform recovery activities with the help of nurses in the recovery program at Hospital

Global stroke burden keeps rising despite falling rates

A new Global Burden of Disease (GBD) study in Neuroepidemiology looks closely at a…